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OBJECTIVE: To use data from the HCIA hospital claims
database to track pharmaceutical use, incidence of ad-
verse events, and costs in patients undergoing PCI.
METHODS: We analyzed hospital claims data from a
nationally representative sample of 11,086 patients who
underwent PCI between October 1996 and September
1997 to determine inpatient pharmaceutical use, patient
outcomes (i.e., repeat PCI, coronary artery bypass sur-
gery [CABG], or death), the incidence of adverse events
(i.e., bleeding), and costs. Analyses were conducted using
a multivariate model to control for patient severity and
other exogenous factors, yielding conservative and upper
bound cost estimates.
RESULTS: Mean total heparin dosage was approxi-
mately 83,000 units per patient per hospital stay. Stents
and abciximab were used in 51% and 21% of patients,
respectively. CABG was necessary in 2.4% of patients
and repeat procedure in more than 5.5% of patients; the
incidence of death was 1.5%. Bleed rates (defined as any
patient receiving a red blood cell transfusion) was 6.3%
throughout the study period with 5.1% of patients re-
quiring a transfusion of two or more units. Even among
non-CABG patients, bleed rates were nearly 5%. Cost for
an uncomplicated PTCA averaged $9555. The incremen-
tal cost for managing patients who suffered an adverse
outcome or event averaged $5745. A less conservative
model incorporating increased length of hospital stay
showed that the average patient with complications in-
curred additional costs of $11,780.
CONCLUSION: Hospital claims databases are a cost-
effective alternative for tracking the costs and outcomes
associated with inpatient pharmaceutical use. In the case
of PCI, hospital claims data offers the ability to track re-
peat procedure, CABG, death, and bleeding rates as well
as costs.
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TOTAL HEALTHCARE UTILIZATION AND 
COSTS ASSOCIATED WITH MIGRAINE IN A 
MEDICAID POPULATION
Joish VN, Cady PC, Culbertson VL
College of Pharmacy, Idaho State University, Pocatello, ID
OBJECTIVE: To compare healthcare use and drug utili-
zation in patients with migraine and patients without mi-
graine headaches.
DESIGN: Retrospective review of Idaho Medicaid claims
database for claims filed during 1993 and during 1997.
METHODS: Inclusion criteria for the migraine patients
were: above the age of 4, with a migraine diagnosis and
one or more prescriptions for migraine medication, en-
rolled in Medicaid during 1993 and in 1997 (n  430).
The control group (n  1720) had to have at least one
non-migraine-related diagnosis and one or more prescrip-
tions during the study period for inclusion. A control
group was matched by age, gender, and geographic re-
gion. A 4:1 match was performed. Use of health services
and drug utilization in four identified treatment settings
and associated costs were compared between the mi-
graineurs and control group before and after removing
migraine-related costs. Differences in costs and utiliza-
tion of calcium-channel-blockers, anti-depressants, anal-
gesics, anti-migraine preparations, beta-blockers and
NSAIDs were analyzed separately.
RESULTS: Significant differences (p  0.05) in costs, in
all four treatment settings, number of procedures and vis-
its and drug utilization were found in both the years (viz.,
1993 and 1997) between the two groups, before and af-
ter removing migraine-related costs. After removing mi-
graine-related services and drugs used specifically for mi-
graine, the number of encounters, procedures in ERs,
physicians’ office, “unknown” setting, and utilization of
analgesics, beta-blockers and NSAIDs remained signifi-
cantly higher in migraineurs, in both years. Utilization of
narcotics was found to be nine times more among mi-
graineurs in 1993 and five times more in 1997.
CONCLUSION: Except for hospital outpatient services,
migraineurs use healthcare services more than a matched
comparison group even after removing migraine-related
costs.
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OBJECTIVE: Post-acute coronary syndrome (post-ACS)
patients experience very different survival patterns during
the acute and chronic phases of their illness. To provide a
clinically relevant life expectancy estimate for post-ACS
patients and subgroups of unstable angina (UA) and re-
cent (6 week) myocardial infarction (MI) patients, we
developed a two-component survival model which ac-
counted for differences in acute and chronic survival and
also extrapolated beyond the available follow-up data.
METHODS: We included UA and MI patients who re-
ceived an initial coronary angiography (cath) at Duke
University Medical Center between March 1984 and De-
cember 1997. Patients with previous cardiac procedures
or valvular disease were excluded. We defined the acute
post-ACS phase as lasting from the initial cath through 1
year follow-up and chronic phase as the second follow-
up year through end of life.
RESULTS: Our population contained 10,398 patients
with 12-year follow-up 95% complete. Initial treatment
strategy, age, body mass index, history of diabetes, cere-
bral or peripheral vascular disease, and congestive heart
failure were predictive of both acute and chronic phase
survival (p  0.05). Recent MI and year of initial cath
were predictive of acute phase survival whereas history of
MI and smoking were predictive of chronic phase sur-
vival (p  0.05). While acute phase mortality was greater
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in MI than in UA patients (11.2% versus 7.1%%), 12-
year cumulative mortality was nearly identical (49.2%
MI versus 49.8% UA) in the two groups. Average post-
ACS life expectancy was 15.604 years (15.460 UA and
15.649 MI).
CONCLUSIONS: Despite significant differences in acute
phase mortality, UA and MI patients have similar life ex-
pectancies.
INDIRECT COSTS
TPIC1
INDIRECT COSTS OF MIGRAINEURS: THREE 
DIFFERENT APPROACHES TO VALUING LOST 
WORKPLACE PRODUCTIVITY
Thornhill JC, Lofland JH
Thomas Jefferson University, Philadelphia, PA, USA
OBJECTIVE: To evaluate application of variables from an
observational study data set to calculate and compare
workplace absenteeism and productivity costs using human
capital approach (HCA) and friction cost approach (FCA).
METHODS: This was a supplemental analysis to a com-
pleted prospective, 6-month observational migraine out-
comes study within a managed care organization (MCO).
Data collection included pharmacy claims, patient occupa-
tion, and patient self-reported workplace absenteeism, and
productivity at baseline, 3 months and 6 months post-
sumatriptan treatment. Patients were included in this sup-
plemental analysis if they completed all three self-reported
surveys and used sumatriptan according to the MCO prior
authorization program. The HCA was calculated as:
[(number days missed due to migraine)  (days worked
with migraine symptoms)(100%  % effectiveness while
working with migraine symptoms)/100%] 	 (daily wage).
The FCA was calculated as (average number of migraines
per month)(average number of lost work days due to mi-
graine)(work hours/day)(dollars of production/employee).
RESULTS: There were 160 patients who met the inclu-
sion criteria for this analysis. The total indirect costs us-
ing the HCA and FCA methodologies were $97,024 and
$124,260, respectively.
CONCLUSION: The methodology assumptions and esti-
mates employed to value lost productivity in this migraine
population significantly impact the results obtained. Pro-
spective data collection may be required to minimize as-
sumptions and accurately capture variables needed to cal-
culate and understand each indirect cost method. Further
evaluation of the post hoc analysis of observational data
sets to evaluate productivity costs is warranted.
TPIC2
IMPACT OF ATTENTION DEFICIT AND 
HYPERACTIVITY DISORDER (ADHD):
A SURVEY OF PRIMARY CAREGIVERS
Jackson SE, Peeples P
Alza Corporation, Palo Alto, CA, USA
ADHD is believed to be one of the most prevalent psychi-
atric disorders of childhood; however, the cost of ADHD
is not well understood.
OBJECTIVE: To examine the impact of ADHD on indi-
rect costs and resource utilization associated with sched-
uled and unscheduled visits to healthcare professionals.
METHODS: In 1997, 150 primary caregivers for ADHD
children completed a telephone survey. Scheduled and
emergency visits to providers were collected for the past
12 months. Indirect costs associated with primary care-
giver work absenteeism or reduced productivity due to
ADHD were also collected.
RESULTS: The mean number of ADHD children per
caregiver was 1.3 (range 1–4); 60% were in sixth grade
or lower. Mean number of visits over 12 months to pedi-
atricians, psychiatrists, psychologists, and counselors for
ADHD was 2.0, 3.8, 3.0, 6.8, respectively. In the past 3
months, 17% of the visits were emergency unscheduled
visits. Parents accompanied their child on 92% of visits,
overall. Sixty-three percent of caregivers reported some
change in their work status as a result of their child’s
ADHD. Of these caregivers, 15% changed job type, 47%
reduced hours worked per week, and 11% stopped
working completely. In the past 4 weeks, caregivers lost
an average of 0.8 days from their primary responsibility
and were 25% less productive on an average of 2.4 days
due to their child’s ADHD. This would result in 39 days
of reduced caregiver productivity per year.
CONCLUSIONS: ADHD in children results in substan-
tial impact on parents due to changes in work status, ab-
senteeism, and productivity loss. Management of ADHD
results in routine scheduled physician visits. Effective
management of ADHD may minimize these costs to em-
ployers and the healthcare system.
TPIC3
THE PRODUCTIVITY COSTS OF
ALLERGIC RHINITIS
Crystal-Peters J, Crown B, Goetzel R
The MEDSTAT Group, Inc., Washington, DC, USA
Productivity losses associated with allergic rhinitis gener-
ally are not a major concern of employers. However,
there are a number of reasons why the productivity costs
associated with allergic rhinitis may be substantial.
OBJECTIVE: In this paper, we estimated absenteeism
costs and reduced productivity associated with allergic
rhinitis.
METHODS: The National Health Interview Survey
(NHIS) was used to obtain information on days lost from
work and lost productivity, due to allergic rhinitis. Wage
estimates for occupational categories, obtained from the
Bureau of Labor Statistics (BLS), were used to calculate
the economic costs.
